Earnings

Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate

Nov 5, 2026 · 07:22 AM ET· updated 2h ago

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year. The company

Why It Matters

Aclaris lost less money per share than people expected this quarter. When a company loses less than forecast, it shows better control of spending.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ACRS3.51

-0.17 (-4.62%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.